Company Filing History:

9 out of 36

Centrexion Therapeutics Corporation

patents

7 out of 1,536

Boehringer Ingelheim International Gmbh

patents

Years Active: 2014-2025

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209094 - CCR2 receptor antagonists and uses thereof (2025-01-28),

2. 11731981 - CCR2 receptor antagonists and uses thereof (2023-08-22),

3. 11046706 - CCR2 receptor antagonists and uses thereof (2021-06-29),

4. 10675268 - Somatostatin receptor subtype 4 (SSTR4) agonists (2020-06-09),

5. 10577336 - Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists (2020-03-03),

6. 10196402 - CCR2 receptor antagonists and uses thereof (2019-02-05),

7. 10183940 - Aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amides as somatostatin receptor subtype 4 (SSTR4) agonists (2019-01-22),

8. 10166214 - Somatostatin receptor subtype 4 (SSTR4) agonists (2019-01-01),

9. 10071974 - Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists (2018-09-11),

10. 9789082 - Somatostatin receptor subtype 4 (SSTR4) agonists (2017-10-17),

11. 9670222 - CCR2 receptor antagonists and uses thereof (2017-06-06),

12. 9371282 - Somatostatin receptor subtype 4 (SSTR4) agonists (2016-06-21),

13. 9012489 - Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament (2015-04-21),

14. 8946218 - CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments (2015-02-03),

15. 8877745 - CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments (2014-11-04),

Title: Rocco Mazzaferro: Innovator in CCR2 Receptor Antagonists

Introduction

Rocco Mazzaferro is a prominent inventor based in San Giuliano Milanese, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of CCR2 receptor antagonists. With a total of 16 patents to his name, his work focuses on innovative solutions for treating pulmonary diseases.

Latest Patents

Among his latest patents, Rocco has developed novel antagonists for CCR2 (CC chemokine receptor 2). These inventions are aimed at providing medicaments for treating various conditions and diseases, especially pulmonary diseases such as asthma and COPD. His research in this area has the potential to improve the quality of life for many patients suffering from these ailments.

Career Highlights

Rocco has worked with notable companies in the pharmaceutical industry, including Centrexion Therapeutics Corporation and Boehringer Ingelheim International GmbH. His experience in these organizations has allowed him to collaborate with leading experts and contribute to groundbreaking research.

Collaborations

Rocco has collaborated with esteemed colleagues such as Riccardo Giovannini and Heiner Ebel. These partnerships have further enhanced his research and development efforts in the field of medicinal chemistry.

Conclusion

Rocco Mazzaferro's innovative work in CCR2 receptor antagonists showcases his dedication to advancing medical treatments for pulmonary diseases. His contributions through patents and collaborations highlight his role as a key figure in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com